Drug Trial Radar · NCT07743983
A Study of BGM0504 in Early T2DM With Obesity
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
372
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Sep 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.
Conditions
- Type 2 Diabetes (T2DM)
Interventions
BGM0504Drug
Administered as a subcutaneous injection once weekly for 52 weeks.
semaglutideDrug
Administered as a subcutaneous injection once weekly for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from BaselineTime frame: Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital(The Affiliated Hospital of Nanjing University Medical School)
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.